Both copyright and Mounjaro are innovative medications designed people manage obesity, but they work through unique mechanisms. copyright primarily regulates glucagon-like peptide-1 (GLP-1) receptors, boosting insulin secretion and reducing appetite . Tirzepatide , conversely , is a dual agonist that impacts both GLP-1 and GIP, possibly leading to